BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35391568)

  • 1. Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study.
    Ruppert K; Geffert C; Clement HW; Bachmann C; Haberhausen M; Schulz E; Fleischhaker C; Biscaldi-Schäfer M
    J Neural Transm (Vienna); 2022 Jul; 129(7):945-959. PubMed ID: 35391568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.
    Guo HL; Wu DD; Fu D; Li Y; Wang J; Zhang YY; Wang WJ; Huang J; Fang WR; Xu J; Hu YH; Liu QQ; Chen F
    Transl Psychiatry; 2024 Mar; 14(1):151. PubMed ID: 38504095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
    Fu D; Guo HL; Hu YH; Chen F
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):98-103. PubMed ID: 36655671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
    CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder.
    Khoodoruth MAS; Ouanes S; Khan YS
    Res Dev Disabil; 2022 Sep; 128():104275. PubMed ID: 35691145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.
    Montoya A; Escobar R; García-Polavieja MJ; Lachno DR; Alda JÁ; Artigas J; Cardo E; García M; Gastaminza X; Gilaberte I
    J Child Neurol; 2011 Jan; 26(1):31-6. PubMed ID: 20525942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
    Sevecke K; Battel S; Dittmann RW; Lehmkuhl G; Döpfner M
    Nervenarzt; 2006 Mar; 77(3):294, 297-300, 302-4 passim. PubMed ID: 16133434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.
    Bakken RJ; Paczkowski M; Kramer HP; Axelson AA; Williams DW; Malcolm SK; Sumner CR; Kelsey DK
    Curr Med Res Opin; 2008 Feb; 24(2):449-60. PubMed ID: 18179733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
    Mazzone L; Reale L; Mannino V; Cocuzza M; Vitiello B
    CNS Drugs; 2011 Jun; 25(6):503-9. PubMed ID: 21649450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder.
    Ghuman JK; Aman MG; Ghuman HS; Reichenbacher T; Gelenberg A; Wright R; Rice S; Fort C
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):155-66. PubMed ID: 19364293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
    Cheng JY; Chen RY; Ko JS; Ng EM
    Psychopharmacology (Berl); 2007 Oct; 194(2):197-209. PubMed ID: 17572882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder.
    Vaughan B; Fegert J; Kratochvil CJ
    Expert Opin Pharmacother; 2009 Mar; 10(4):669-76. PubMed ID: 19239401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
    Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
    Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.